aacr.org· AACR·2026-04-22 06:30· 2026-04-22Score60

Clinical Trials Plenary: New Results from Immunotherapy Regimen Trials

In brief

Final Clinical Trials Plenary, 'Advances in Immunotherapy', chaired by Ryan Sullivan (Massachusetts General Hospital). Alberto Giovanni Leone (Istituto Nazionale dei Tumori) presented phase II INFINITY data on tremelimumab plus durvalumab for organ preservation in MSI-high tumours.

Conference abstracts

6547NCT06526104matched by 药名 durvalumab

Phase II single arm study of tremelimumab and durvalumab (MEDI4736) (T300+D) in advanced hepatocellular carcinomas with Child-Pugh-B cirrhosis (STRIDE in CP-B)

Sukeshi Patel Arora, Lorena Fuentes, James Denno, Jennifer Moseley, Brittany M. Altermatt, Elizabeth Diaz, Joshua Ray Smith, Joel Michalek, Lei Zheng

Read the abstract →

CT230NCT04817826matched by 药名 durvalumab

STRIDE regimen of tremelimumab and durvalumab as non-operative management strategy of microsatellite instability-high (MSI-H) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): Final results of the cohort 2 of INFINITY study by GONO GI

Alberto Giovanni Leone, Alessandra Raimondi, Paolo Manca, Sabina Murgioni, Giovanni G. Cardellino, Alessandro Bittoni, Antonia Strippoli, Maria Bencivenga, Federica Palermo, Floriana Nappo, Silvio K. Garattini, Thereasa Rich, Gaia Rebecchi, Roberta Fazio, Camilla Damonte, Margherita Ambrosini, Cecilia Villa, Greta Gronchi, Sara Lonardi, Filippo Pietrantonio

Read the abstract →

Source: aacr.org · aacr.org